AARD insider trading
HealthcareAardvark Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Company website: aardvarktherapeutics.com
AARD insider activity at a glance
FilingIQ tracks 26 insider transactions for AARD in filings since Feb 19, 2025. The most recent transaction is dated Sep 11, 2026.
Across the full history, 13 open-market purchases
and 2 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on AARD insider trades is 53.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest AARD Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for AARD?
- FilingIQ tracks 26 Form 4 insider transactions for AARD (Aardvark Therapeutics, Inc.), covering filings from Feb 19, 2025 onwards. 2 of those are dated within the last 90 days.
- Are AARD insiders net buyers or net sellers?
- Across the full Form 4 history for AARD, 13 transactions (50%) were open-market purchases and 2 (8%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AARD insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is AARD in?
- Aardvark Therapeutics, Inc. (AARD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $265.63M.
Methodology & sources
Every AARD insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.